Haisco Pharmaceutical: Share pledge, equity issuance approved, and grant received

Haisco Pharmaceutical Group announced that its major shareholder, Fan Xiulian, pledged 23.6 million shares, representing 1.09% of her holdings and 0.21% of the company's total share capital, to Guotai Junan Securities Co., Ltd. The pledge is for business operation purposes and is valid until December 17, 2026. This transaction increased Fan Xiulian's total pledged shares to 55.59 million, or 25.58% of her total shares, representing 4.96% of the company's total share capital.

The company also received approval from the Shenzhen Stock Exchange's Listing Review Center for its application to issue shares to specific targets. This approval signals a step forward in its equity financing plans, though it still awaits registration approval from the China Securities Regulatory Commission.

Furthermore, Haisco Pharmaceutical Group received a government grant of 120 million yuan on December 18, 2025. This grant, classified as income-related and directly recognized in other income, is expected to increase the company's 2025 total profit by 120 million yuan, representing 30.34% of its 2024 audited net profit attributable to shareholders.